Ann: onCARlytics with Artemis T cells abstract presented at ASGCT, page-65

Others have probably read this ..... "Small Caps " summed it up nicely I think & sorry to repeat
Once again for may this announcement will be meaningless , because they have little knowledge
At some point in time they will probably with they had taken the time to gain a bit of knowledge ,
recognize the clues and the incredible progress IMU have made on so many fronts
But thats OK .... therein lies the opportunity LOL



FacebookTwitterLinkedInEmailPrint

Imugene (ASX: IMU) has unveiled “impressive” pre-clinical in vivo anti-tumour responses using its onCARlytics technology in combination with Eureka Therapeutics’ Artemis’ T cell platform on models with liver cancer.
The company presented an abstract titled ‘Effective combination immunotherapy using onCARlytics and Artemis CD19 T cells against hepatocellular carcinoma’ at the American Society of Gene and Cell Therapy’s Annual Meeting in the United States.
Hepatocellular carcinoma (HCC) is the most frequent type of liver cancer and the sixth most common cancer worldwide.
The abstract was based on pre-clinical research using the combination therapy in a human xenograft HepG2 model.
This combination therapy involved harnessing the capability of oncolytic viruses (OV) and developing a chimeric vaccinia-based OV called CF330CD19t (onCARlytics) to use CD19-specific T cells to target solid tumours.
“In order to target CD19t expressed on the surface of solid tumour cells, we combined onCARlytics with CD19 Artemis T cells, a CD19-targeting adoptively engineered T cell powered by the Artemis antibody-T cell receptor (AbTCR) platform,” the report stated.
It noted the combination therapy “demonstrated impressive in vivo anti-tumour responses” in the HepG2 model.
By using this strategy, Imugene anticipates the combination therapy can be broadened to target an “array of solid cancers”.
The full presentation on the results will be given later in May at the 26th American Society of Gene and Cell Therapy’s Annual Meeting.